UFCoDES Profile Banner
UF Center for Drug Evaluation and Safety Profile
UF Center for Drug Evaluation and Safety

@UFCoDES

Followers
608
Following
543
Statuses
752

Official account of the @UF Center for Drug Evaluation and Safety. @UFHealth @UFPharmacy #DrugSafety #RWE #RealWorldData #DataScience. RTs are not endorsements

Gainesville, FL
Joined June 2019
Don't wanna be here? Send us removal request.
@UFCoDES
UF Center for Drug Evaluation and Safety
4 months
POP graduate student Henry Hung-Kai Chen places third in student abstract competition at ISPE Annual Meeting
0
0
3
@UFCoDES
UF Center for Drug Evaluation and Safety
4 months
UF Health researchers receive NIH R01 grant to develop social risk management tool for people living with dementia @Serena_JG
0
0
0
@UFCoDES
UF Center for Drug Evaluation and Safety
4 months
New publication by @UFCoDES trainee @SJugl1 in @LiebertPub –Legalization of Smokable Medical Cannabis and Changes in the Dispensed Amount of Δ-9 Tetrahydrocannabinol Per Patient | Cannabis and Cannabinoid Research @amiegoodin @AlmutWinterste1
0
0
1
@UFCoDES
UF Center for Drug Evaluation and Safety
4 months
New publication by @AlmutWinterste1 and @Serena_JG in @IntPharmacoEpi Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremi… @UFPharmacy
0
1
2
@UFCoDES
UF Center for Drug Evaluation and Safety
4 months
New publication by @UFCoDES trainee @TangHuilin in @BioMedCentral – Association of education attainment, smoking status, and alcohol use disorder with dementia risk in older adults: a… @Serena_JG @UFPharmacy
0
0
1
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication by @Serena_JG in Diabetes, Obesity and Metabolism – Sodium-glucose cotransporter 2 inhibitors and the risk of #Parkinson disease in real-world patients with type 2 diabetes @UFPharmacy
0
0
0
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication co-authored by @segal_rich in @ADCESdiabetes Medication Engagement, Determinants of Health, and A1C Levels Among Adults With Type 2 Diabetes within a Tribal Health System @UFPharmacy
0
0
0
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication by @UFCoDES trainee @tSHCw in @amcporg– Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor...
0
1
1
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication by @UFCoDES trainee @RiazMunaza in @JInternMed– Hospitalization after #hydroxychloroquine initiation in patients with heart failure with preserved #ejection fraction… @UFPharmacy
0
1
1
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication by @UFCoDES trainee @TangHuilin in @movedisorder Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.29992
0
0
0
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication by @UFCoDES trainee @GraceWahaha in @JAMANetworkOpen #Injurious Fall Risk Differences Among Older Adults Being Treated for #Depression @jennyciganic @amiegoodin @UFPharmacy
0
0
0
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication co-authored by @SteveSmithUF in @AMIAinformatics - Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program @UFPharmacy
0
0
0
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication co-authored by @AlmutWinterste1 in @ASCPT_ClinPharm – Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators @UFPharmacy
0
1
1
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication co-authored by @AlmutWinterste1 in @ASCPT_ClinPharm -Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies @UFPharmacy
0
1
1
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication co-authored by @Serena_JG in American Journal of Cardiovascular Drugs –#COVID-19 Diagnosis, Oral #Anticoagulation, and #Stroke Risk in Patients with Atrial Fibrillation @UFPharmacy
0
0
0
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication by @amiegoodin in @IntPharmacoEpi – Risk of #Suicidal Ideation and Behavior Following Early-Onset #Idiopathic Restless Legs Syndrome Treatment @UFPharmacy
0
0
0
@UFCoDES
UF Center for Drug Evaluation and Safety
5 months
New publication by @AlmutWinterste1 @amiegoodin in @KargerPublisher – Reasons for Use and Perceived Effects of #Medical #Cannabis: A Cross-Sectional Statewide Survey @UFPharmacy
0
0
1
@UFCoDES
UF Center for Drug Evaluation and Safety
7 months
Dr. Riaz’s heart failure study was recognized at the 2024 ISPOR Conference. @RiazMunaza, Ph.D., is a 2023 graduate of the University of Florida College of Pharmacy’s department of pharmaceutical outcomes and policy. @UFPharmacy
0
1
3
@UFCoDES
UF Center for Drug Evaluation and Safety
7 months
The University of Florida College of Pharmacy- Department of Pharmaceutical Outcomes & Policy congratulates @SteveSmithUF who was promoted to associate professor on July 1, 2024. @UFPharmacy
0
0
5
@UFCoDES
UF Center for Drug Evaluation and Safety
7 months
New publication co-authored by @AlmutWinterste1 and Dr. Masoud Rouhizadeh in @_Anesthesiology - #Cannabis Use and #Inhalational Anesthesia Administration in Older Adults: A Propensity Matched Retrospective Cohort Study @UFPharmacy
0
0
0